Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature

[img]
Preview
PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
356kB

Item Type:Review
Title:MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature
Creators Name:Jarius, S. and Ruprecht, K. and Stellmann, J.P. and Huss, A. and Ayzenberg, I. and Willing, A. and Trebst, C. and Pawlitzki, M. and Abdelhak, A. and Grüter, T. and Leypoldt, F. and Haas, J. and Kleiter, I. and Tumani, H. and Fechner, K. and Reindl, M. and Paul, F. and Wildemann, B.
Abstract:BACKGROUND: Antibodies to human full-length myelin oligodendrocyte glycoprotein (MOG-IgG) as detected by new-generation cell-based assays have recently been described in patients presenting with acute demyelinating disease of the central nervous system, including patients previously diagnosed with multiple sclerosis (MS). However, only limited data are available on the relevance of MOG-IgG testing in patients with chronic progressive demyelinating disease. It is unclear if patients with primary progressive MS (PPMS) or secondary progressive MS (SPMS) should routinely be tested for MOG-IgG. OBJECTIVE: To evaluate the frequency of MOG-IgG among patients classified as having PPMS or SPMS based on current diagnostic criteria. METHODS: For this purpose, we retrospectively tested serum samples of 200 patients with PPMS or SPMS for MOG-IgG using cell-based assays. In addition, we performed a review of the entire English language literature on MOG-IgG published between 2011 and 2017. RESULTS: None of 139 PPMS and 61 SPMS patients tested was positive for MOG-IgG. Based on a review of the literature, we identified 35 further MOG-IgG tests in patients with PPMS and 55 in patients with SPMS; the only reportedly positive sample was positive just at threshold level and was tested in a non-IgG-specific assay. In total, a single borderline positive result was observed among 290 tests. CONCLUSION: Our data suggest that MOG-IgG is absent or extremely rare among patients with PPMS or SPMS. Routine screening of patients with typical PPMS/SPMS for MOG-IgG seems not to be justified.
Keywords:Myelin Oligodendrocyte Glycoprotein (MOG), Antibodies, Immunoglobulin G, MOG-IgG, Primary Chronic Progressive MS (PPMS), Secondary Chronic Progressive MS (SPMS), Neuromyelitis Optica Spectrum Disorders (NMOSD)
Source:Journal of Neuroinflammation
ISSN:1742-2094
Publisher:BioMed Central (U.K.)
Volume:15
Number:1
Page Range:88
Date:19 March 2018
Official Publication:https://doi.org/10.1186/s12974-018-1108-6
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library